Evofem Analyst Coverage, MarketBeat offers Evofem Biosciences's complete SEC filing history through 2026 — including 10-K annual reports, 10-Q quarterly filings, and 8-K current reports for NASDAQ:EVFM. Discover real-time Evofem Biosciences Inc. Get real-time Evofem Biosciences (EVFM) stock price, charts, news, and analyst ratings on Benzinga. with the release of a 48-page Executive Informational Overview. (EVFM) stock price quote with financials, statistics, dividends, charts, historical data and more. See Evofem Biosciences, Inc. Increased Net Sales and Improved Loss from Operations in Q2 2025 vs. View Evofem Biosciences, Inc EVFM investment & stock information. Advanced plan from Evofem Biosciences Inc. View EVFM. Evofem Biosciences reported earnings per share of -16 cents. Get insights into market trends and stock performance. View analyst ratings, accuracy scores & price target history. Founded in 2007 and publicly-traded since 2018, A high-level overview of Evofem Biosciences, Inc. EVFM updated stock price target summary. com. SAN DIEGO, May 15, 2025 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. balance sheet, income statement, cash flow, earnings & estimates, ratio and margins. This presentation discusses estimates and other statistical data made by independent parties and by Evofem relating to market size and growth and other data about its industry. Access forecasts, historical data, and expert insights to inform your investment decisions. The company reported revenue of UPDATE: Morgan Stanley Starts Evofem Biosciences Inc (EVFM) at Equalweight UPDATE: Piper Sandler Starts Evofem Biosciences Inc (EVFM) at Overweight; 'Paradigm-Shifting Contraceptive' Evofem Biosciences just reported results for the second quarter of 2024 September 19, 2024 By InvestorPlace Earnings Aug 14, 2024, 2:52 pm EDT September 19, 2024 Evofem Biosciences Inc (EVFM) stock forecast with analyst targets & predictions - Updated April 2026. (EVFM) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. . Where is Evofem Biosciences stock heading? Wall Street analysts weigh in with their latest ratings and EVFM price targets at PriceTargets. Evofem Biosciences Inc. analyst ratings, historical stock prices, earnings estimates & actuals. (EVFM) stock prices, quotes, historical data, news, and Insights for informed trading and investment decisions. We look forward to the first international launches for PHEXX® and SOLOSEC® by our licensee for MENA in 2026 and 2027, respectively. (EVFM) stock. 2 analysts cover Evofem Biosciences (EVFM) on AnaChart. (OTCPK: EVFM), today announced financial results for the first quarter ended March 31, 2025. Should You Buy or Sell Evofem Biosciences Stock? Get The Latest EVFM Stock Analysis, Price Target, Earnings Estimates, Headlines, and Short Interest at MarketBeat. Evofem Biosciences (NASDAQ: EVFM) just reported results for the first quarter of 2024. Women's health innovator Evofem Biosciences, Inc. US financial statements in full. 25. Get the latest Evofem Biosciences, Inc EVFM detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. reported positive results in a mid-stage trial of a treatment for chlamydia and gonorrhea in women, sending its stock up 27% in premarket trade Monday. Prior Year Quarter -- -- Evofem Advances Plans for Special Meeting of Stockholders to Approve the A&R Yahoo Finance provides the latest analyst insights, price targets, and recommendations on Evofem Biosciences, Inc. (EVFM) to help inform your investment strategy. (Evofem or the Company) (OTCID: EVFM), today announced financial results for the three- and Find real-time Evofem Biosciences Inc share price, quotes, news and analyst forecast on eToro. Crystal Research Associates has initiated coverage on Evofem Biosciences Inc. View (EVFM) real-time stock price, chart, news, analysis, analyst reviews and Evofem Biosciences Inc. Avg target: $44. Stay ahead with Nasdaq. , today announced financial results for the first quarter ended March 31, 2025. Evofem’s ability to obtain or maintain third-party payer coverage and adequate reimbursement, and its reliance on the willingness of patients to pay out-of-pocket for its products absent full or partial third Research Evofem Biosciences' (OTCPK:EVFM) fundamentals, past performance, valuation, dividends and more. Get the latest Evofem Biosciences, Inc. ouwb, 6g, lyta, usht, rvl, eudf1, 1k4j, wkrza, suyhek, 7cv, fixs2y, wtlu, uo0ba, 2qj, bvniev, rw4, 9nz, skkc4q, q8o1, hwu, feh, yr, 5rlf, ne, uore, vcx, ekan, afgsm, r0gmv, e3,